155 related articles for article (PubMed ID: 36634212)
1. Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001.
Li X; Abrahams C; Yu A; Embry M; Henningsen R; DeAlmeida V; Matheny S; Kline T; Yam A; Stafford R; Hallam T; Lupher M; Molina A
Oncotarget; 2023 Jan; 14():1-13. PubMed ID: 36634212
[TBL] [Abstract][Full Text] [Related]
2. Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001.
Abrahams CL; Li X; Embry M; Yu A; Krimm S; Krueger S; Greenland NY; Wen KW; Jones C; DeAlmeida V; Solis WA; Matheny S; Kline T; Yam AY; Stafford R; Wiita AP; Hallam T; Lupher M; Molina A
Oncotarget; 2018 Dec; 9(102):37700-37714. PubMed ID: 30701025
[TBL] [Abstract][Full Text] [Related]
3. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.
Li D; Poon KA; Yu SF; Dere R; Go M; Lau J; Zheng B; Elkins K; Danilenko D; Kozak KR; Chan P; Chuh J; Shi X; Nazzal D; Fuh F; McBride J; Ramakrishnan V; de Tute R; Rawstron A; Jack AS; Deng R; Chu YW; Dornan D; Williams M; Ho W; Ebens A; Prabhu S; Polson AG
Mol Cancer Ther; 2013 Jul; 12(7):1255-65. PubMed ID: 23598530
[TBL] [Abstract][Full Text] [Related]
4. Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemia.
Le Q; Tang T; Leonti A; Castro S; McKay CN; Perkins L; Pardo L; Kirkey D; Hylkema T; Call L; Manselle M; Abrahams C; Bedard K; Molina A; Brodersen LE; Loken MR; Tarlock K; Meshinchi S; Loeb KR
Blood Adv; 2023 May; 7(9):1666-1670. PubMed ID: 36595452
[No Abstract] [Full Text] [Related]
5. High frequency of CD74 expression in lymphomas: implications for targeted therapy using a novel anti-CD74-drug conjugate.
Zhao S; Molina A; Yu A; Hanson J; Cheung H; Li X; Natkunam Y
J Pathol Clin Res; 2019 Jan; 5(1):12-24. PubMed ID: 30191677
[TBL] [Abstract][Full Text] [Related]
6. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
7. Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers.
Li X; Zhou S; Abrahams CL; Krimm S; Smith J; Bajjuri K; Stephenson HT; Henningsen R; Hanson J; Heibeck TH; Calarese D; Tran C; Yin G; Stafford RL; Yam AY; Kline T; De Almeida VI; Sato AK; Lupher M; Bedard K; Hallam TJ
Mol Cancer Ther; 2023 Feb; 22(2):155-167. PubMed ID: 36459691
[TBL] [Abstract][Full Text] [Related]
8. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.
Pereira DS; Guevara CI; Jin L; Mbong N; Verlinsky A; Hsu SJ; Aviña H; Karki S; Abad JD; Yang P; Moon SJ; Malik F; Choi MY; An Z; Morrison K; Challita-Eid PM; Doñate F; Joseph IB; Kipps TJ; Dick JE; Stover DR
Mol Cancer Ther; 2015 Jul; 14(7):1650-60. PubMed ID: 25934707
[TBL] [Abstract][Full Text] [Related]
9. A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models.
Chan WK; Williams J; Sorathia K; Pray B; Abusaleh K; Bian Z; Sharma A; Hout I; Nishat S; Hanel W; Sloan SL; Yasin A; Denlinger N; Zhang X; Muthusamy N; Vasu S; de Lima M; Yang Y; Baiocchi R; Alinari L
Exp Hematol Oncol; 2023 Sep; 12(1):79. PubMed ID: 37740214
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies.
Stein R; Qu Z; Cardillo TM; Chen S; Rosario A; Horak ID; Hansen HJ; Goldenberg DM
Blood; 2004 Dec; 104(12):3705-11. PubMed ID: 15297317
[TBL] [Abstract][Full Text] [Related]
11. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
[TBL] [Abstract][Full Text] [Related]
12. Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models.
Gaudio E; Tarantelli C; Spriano F; Guidetti F; Sartori G; Bordone R; Arribas AJ; Cascione L; Bigioni M; Merlino G; Fiascarelli A; Bressan A; Adjeiwaa Mensah A; Golino G; Lucchini R; Bernasconi E; Rossi D; Zucca E; Stussi G; Stathis A; Boyd RS; Dusek RL; Bisht A; Attanasio N; Rohlff C; Pellacani A; Binaschi M; Bertoni F
Haematologica; 2020 Nov; 105(11):2584-2591. PubMed ID: 33131247
[TBL] [Abstract][Full Text] [Related]
13. Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.
Mehta A; Forero-Torres A
Curr Oncol Rep; 2015 Sep; 17(9):41. PubMed ID: 26194424
[TBL] [Abstract][Full Text] [Related]
14. A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30
Wang R; Li L; Zhang S; Li Y; Wang X; Miao Q; Zhen Y
Mol Oncol; 2018 Mar; 12(3):339-355. PubMed ID: 29316337
[TBL] [Abstract][Full Text] [Related]
15. CD74 is expressed by multiple myeloma and is a promising target for therapy.
Burton JD; Ely S; Reddy PK; Stein R; Gold DV; Cardillo TM; Goldenberg DM
Clin Cancer Res; 2004 Oct; 10(19):6606-11. PubMed ID: 15475450
[TBL] [Abstract][Full Text] [Related]
16. TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors.
Gymnopoulos M; Betancourt O; Blot V; Fujita R; Galvan D; Lieuw V; Nguyen S; Snedden J; Stewart C; Villicana J; Wojciak J; Wong E; Pardo R; Patel N; D'Hooge F; Vijayakrishnan B; Barry C; Hartley JA; Howard PW; Newman R; Coronella J
Mol Oncol; 2020 Jan; 14(1):54-68. PubMed ID: 31736230
[TBL] [Abstract][Full Text] [Related]
17. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
Sapra P; Stein R; Pickett J; Qu Z; Govindan SV; Cardillo TM; Hansen HJ; Horak ID; Griffiths GL; Goldenberg DM
Clin Cancer Res; 2005 Jul; 11(14):5257-64. PubMed ID: 16033844
[TBL] [Abstract][Full Text] [Related]
18. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies.
Zammarchi F; Corbett S; Adams L; Tyrer PC; Kiakos K; Janghra N; Marafioti T; Britten CE; Havenith CEG; Chivers S; D'Hooge F; Williams DG; Tiberghien A; Howard PW; Hartley JA; van Berkel PH
Blood; 2018 Mar; 131(10):1094-1105. PubMed ID: 29298756
[TBL] [Abstract][Full Text] [Related]
19. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
[TBL] [Abstract][Full Text] [Related]
20. Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma.
Sherbenou DW; Su Y; Behrens CR; Aftab BT; Perez de Acha O; Murnane M; Bearrows SC; Hann BC; Wolf JL; Martin TG; Liu B
Clin Cancer Res; 2020 Nov; 26(22):6028-6038. PubMed ID: 32917735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
